The selective cytotoxic effects of BLF1 and RocA observed in MYCN-expressing SHEP-21N cells suggests that future immunotoxins and eIF4A small molecule inhibitors have potential as future therapeutics in the treatment of neuroblastomas exhibiting MYCN amplification. The gene discussed is MYCN; the disease is neuroblastoma.